Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel J Cook

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 7, 2021
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutationsLaura F Newell, Jennifer Dunlap, Ken Gatter, et al.
Cytotherapy|January 23, 2023
Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse ratesGeorgeann Booth, Yun Yu, Rogelyn P Harlan, et al.
Transplantation and Cellular Therapy|April 26, 2021
Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or RelapseLaura F Newell, Todd Williams, James Liu, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Cancers|June 12, 2026
Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot StudyLaura F Newell, Eric Twohey, Jason Sweetnam, et al.
Blood Advances|July 14, 2026
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS TrialJeffery J Auletta, Joseph Stanek, Stephanie Bo-Subait, et al.
Blood Advances|December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Blood Neoplasia|January 15, 2026
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trialGiovanni Martinelli, Scott R Solomon, Sudipto Mukherjee, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Blood Cancer Discovery|May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN studyCurtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 7, 2021
Graft-versus-host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutationsLaura F Newell, Jennifer Dunlap, Ken Gatter, et al.
Cytotherapy|January 23, 2023
Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse ratesGeorgeann Booth, Yun Yu, Rogelyn P Harlan, et al.
Transplantation and Cellular Therapy|April 26, 2021
Engrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosuppressive Therapy, but no Adverse Impact on Overall Survival or RelapseLaura F Newell, Todd Williams, James Liu, et al.
Leukemia & Lymphoma|August 12, 2023
Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with <i>RARA</i> gene overexpressionEytan M Stein, Stephane de Botton, Thomas Cluzeau, et al.
Cancers|June 12, 2026
Attenuation of Immune Senescence Markers After Intensive Cancer Therapy Through Resistance Training: A Pilot StudyLaura F Newell, Eric Twohey, Jason Sweetnam, et al.
Blood Advances|July 14, 2026
Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS TrialJeffery J Auletta, Joseph Stanek, Stephanie Bo-Subait, et al.
Blood Advances|December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Blood Neoplasia|January 15, 2026
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trialGiovanni Martinelli, Scott R Solomon, Sudipto Mukherjee, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Blood Cancer Discovery|May 21, 2025
Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN studyCurtis A Lachowiez, Mael Heiblig, Gaspar Aspas Requena, et al.
Pageof 4